- American equities open in the red, though are still heading for a winning week
- US Wholesale Inventories dip unexpectedly
- Amedisys and UnitedHealth merger deal still in the game
Wall Street started Friday’s session in low spirits, with all major indices giving up some ground at the end of a largely successful month. Nasdaq is down 2%, S&P500 loses 1.3%, small-cup Russell 2000 retreats 0.6% and Dow Jones trades 0.7% lower.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appUS Wholesale Inventories unexpectedly decreased by 0.2%, contrary to the forecasted 0.1% increase, signaling a faster turnover of goods and potentially higher consumer demand. While this drop could be bullish for the USD, it also raises concerns about supply chain efficiency and its broader impact on the economy.
US100 (D1)
The Nasdaq, represented by the US100 contract, continues its pullback after hitting the ATH resistance around 22111. Although the momentum of the Santa Claus Rally may be over, the tech heavy index is set to finish the year with a sizeable 30-percent gain. The index may bounce back from its most recent support of about 21400, which is currently leveled at the 30-days EMA. The bearish reversal might be possible, should the profit-taking continue pushing the index down below 21250 mark (aka post-FOMC low). RSI remains neutral at around 55, while MACD histogram still suggests weakening momentum.
Source: xStation5
Corporate news:
- Amedisys (AMED.US), UnitedHealth (UNH.US): home-care provider and health insurer have extended the deadline for their $3.3 billion merger to 2025, following legal challenges from the U.S. Department of Justice (DOJ) and several states, which are concerned the deal could reduce competition in the home health services market. The extension grants the companies until 10 days after the final court decision or December 31, 2025, to close the deal, and includes a regulatory break fee of up to $325 million if required asset divestitures are not made by May 1. Despite the scrutiny, Amedisys shares rise 4.15% at the start of the session.
- Arena Group Holdings: the media company has received approval for its plan to regain compliance with NYSE American's listing standards, with a deadline to achieve full compliance by April 2026. The owner of media brands like TheStreet and Parade Media, was facing challenges in meeting stockholder equity requirements but has shown strong revenue growth of 45% over the past year. Arena Group is also undergoing leadership changes, including the appointment of a new CEO and Principal Financial Officer, while dealing with a legal dispute over alleged theft of proprietary technology. Arena Group's shares are adding 9%.
- BioNTech (BNTX.US): the company reached two settlements over royalty payments related to its COVID-19 vaccine, agreeing to pay $791.5 million to the U.S. National Institutes of Health (NIH) and $467 million to the University of Pennsylvania (Penn). These payments resolve a default notice from the NIH and a lawsuit from Penn, which claimed BioNTech underpaid royalties for using foundational mRNA technology. The settlements include a revised license agreement and an understanding that Pfizer will reimburse BioNTech for a portion of the royalties, but no admission of liability was made by the company. BioNTech is currently up 0.6%.
- Progyny (PGNY.US): the fertility medication provider’s stock adds 11% following a purchase of 150k shares worth of $2.2 mln, made by the company Executive Chairman David J. Schlanger.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
